RxDoctor Payments Data

Jennifer Fleer

Family · West Columbia, SCNPI 1760854145

Payments from drug & device makers

$665in general payments, 2019–2025

Across 12 payments — averaging $55.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$274
  • AstraZeneca$123
  • Avanir Pharmaceuticals, Inc.$122
  • Mylan Specialty L.p.$45
  • Laborie Medical Technologies Corp.$24
  • Siemens Medical Solutions USA, Inc.$23
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$665 in reported general payments places this provider in the 55th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$238,423
Medicare patients
289
Services billed
2,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban245$73,048
EntrestoSacubitril/Valsartan73$25,267
JardianceEmpagliflozin81$24,008
MyrbetriqMirabegron49$15,840
XareltoRivaroxaban46$12,993
Lacosamide31$9,865
TrulicityDulaglutide12$9,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,984
Repatha SureclickEvolocumab12$7,149
Divalproex Sodium97$6,866
Duloxetine Hcl98$6,569
Spiriva RespimatTiotropium Bromide13$5,886
Divalproex Sodium ErDivalproex Sodium93$5,787
Potassium Chloride141$5,773
Atorvastatin Calcium253$4,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$21$9,85612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,248 family providers in South Carolina.

Other family in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →